KIADIS PHARMA N V ORDINARY SHARES NETHE (OTCMKTS:KIADF)’s Stock Is Buy After Less Market Selling
March 5, 2018 - By Henry Gaston
The stock of KIADIS PHARMA N V ORDINARY SHARES NETHE (OTCMKTS:KIADF) registered a decrease of 42.9% in short interest. KIADF’s total short interest was 41,400 shares in March as published by FINRA. Its down 42.9% from 72,500 shares, reported previously. With 100 shares average volume, it will take short sellers 414 days to cover their KIADF’s short positions. The short interest to KIADIS PHARMA N V ORDINARY SHARES NETHE’s float is 0.36%.
It closed at $14.148899 lastly. It is down 0.00% since March 5, 2017 and is . It has underperformed by 16.70% the S&P500.
Kiadis Pharma N.V., a clinical stage biopharmaceutical company, focuses on the research and development of cell immunotherapy products for the treatment of blood cancers and inherited blood disorders in the Netherlands. The company has market cap of $254.53 million. The firm focuses on therapeutic indications, including leukaemia, a common form of blood cancer; and thalassemia, an inherited blood disorder. It currently has negative earnings. The Company’s products comprise ATIR101 , a Phase II clinical trial product, which addresses the risk and limitations of hematopoietic stem cell transplantation in blood cancer; and ATIR201, which is in Phase I/II clinical development for inherited blood disorders with an initial focus on thalassemia.
More notable recent Kiadis Pharma N.V. (OTCMKTS:KIADF) news were published by: Businesswire.com which released: “Kiadis Pharma appoints Dr. Andrew Sandler as Chief Medical Officer” on September 29, 2017, also Businesswire.com with their article: “Kiadis Pharma NV: Planned Management Team Changes” published on December 08, 2016, Businesswire.com published: “Kiadis Pharma Announces Participation at Three Upcoming Investor Events” on November 08, 2017. More interesting news about Kiadis Pharma N.V. (OTCMKTS:KIADF) were released by: Businesswire.com and their article: “Kiadis Pharma Provides Update on the Marketing Authorization Application …” published on September 27, 2017 as well as Businesswire.com‘s news article titled: “Kiadis Pharma proposes former Cipla CEO Subhanu Saxena as new Supervisory …” with publication date: January 16, 2018.
Kiadis Pharma N.V.-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.